Clinical trialNCT03315039CompletedPhase 1/PHASE2Interventional

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

SponsorMoleculin Biotech, Inc.Enrollment7Leukemia, Myeloid, Acute

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Robert Shepard, MD
Moleculin Biotech, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Uc San Diego Health
La Jolla, California, United States
University of Florida
Gainesville, Florida, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Southwest Cancer Center
Lubbock, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Liposomal Annamycin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Mar 2018
Primary completion: 14 Jan 2020
Completion: 20 Jun 2020
Last update posted: 10 Mar 2022
Registered enrollment: 7
Registry id: NCT03315039

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.